Candel therapeutics appoints three new members to its board of directors

Needham, mass., aug. 01, 2022 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today announced the appointment of three new members to its board: gary nabel, md, phd, renowned virologist and immunologist; joseph c. papa, prominent business leader; and renee gaeta, strategic financial expert, effective august 8, 2022. these new members replace current board members: alan e. smith, phd, shaan ghandi, md, d.phil, and udi meirav, phd, maintaining candel's nine-seat board.
CADL Ratings Summary
CADL Quant Ranking